| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
88,060,000 |
| Market
Cap: |
2.38(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$21 - $46.14 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 749 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Veracyte is a genomic diagnostics company. Co. develops tests that address clinical needs in the diagnosis, prognosis and treatment of cancer and other diseases. Co. provides tests in: thyroid cancer via its Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas; prostate cancer via its Decipher Biopsy and Radical Prostatectomy Genomic Classifiers; breast cancer via its Prosigna Breast Cancer Assay; lung cancer via its Percepta GSC and Percepta Nasal Swab Test; interstitial lung diseases including idiopathic pulmonary fibrosis via its Envisia Genomic Classifier; bladder cancer via its Decipher Bladder Genomic Classifier; and colon cancer via its Immunoscore Colon Cancer Test.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
11,988 |
97,548 |
274,083 |
382,599 |
| Total Sell Value |
$321,165 |
$3,239,699 |
$9,545,512 |
$12,561,109 |
| Total People Sold |
3 |
7 |
11 |
12 |
| Total Sell Transactions |
3 |
10 |
35 |
49 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jones Evan/ Fa |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,321 |
43,664 |
|
- |
|
| Epstein Robert S |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,321 |
73,919 |
|
- |
|
| Miller Thomas F. |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,321 |
25,828 |
|
- |
|
| Shafer David Brent |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,321 |
25,828 |
|
- |
|
| Holstein Jens |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,321 |
37,199 |
|
- |
|
| Barr Eliav |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,321 |
51,189 |
|
- |
|
| Eastham Karin |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,321 |
23,228 |
|
- |
|
| Bhanji Muna |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,321 |
39,310 |
|
- |
|
| Eastham Karin |
Director |
– • – |
2025-06-13 |
4 |
AS |
$26.66 |
$122,388 |
D/D |
(4,590) |
13,907 |
|
4% |
|
| Bhanji Muna |
Director |
– • – |
2025-06-13 |
4 |
AS |
$26.67 |
$122,367 |
D/D |
(4,589) |
29,989 |
|
4% |
|
| Leite John |
Chief Commercial Officer-CLIA |
• – – |
2025-06-04 |
4 |
AS |
$27.20 |
$76,410 |
D/D |
(2,809) |
94,540 |
|
0% |
|
| Mcguire Annie |
SVP, General Counsel |
• – – |
2025-06-02 |
4 |
D |
$26.74 |
$93,724 |
D/D |
(3,505) |
97,003 |
|
- |
|
| Febbo Phillip G. |
Chief Scientific & Med Officer |
• – – |
2025-06-02 |
4 |
D |
$26.74 |
$79,017 |
D/D |
(2,955) |
103,745 |
|
- |
|
| Stapley Marc |
Chief Executive Officer |
• • – |
2025-06-02 |
4 |
D |
$26.74 |
$251,329 |
D/D |
(9,399) |
349,237 |
|
- |
|
| Chambers Rebecca |
Chief Financial Officer |
• – – |
2025-06-02 |
4 |
D |
$26.74 |
$143,594 |
D/D |
(5,370) |
138,529 |
|
- |
|
| Leite John |
Chief Commercial Officer-CLIA |
• – – |
2025-06-02 |
4 |
D |
$26.74 |
$77,546 |
D/D |
(2,900) |
97,349 |
|
- |
|
| Wygant Jonathan |
VP, Chief Accounting Officer |
• – – |
2025-06-02 |
4 |
D |
$26.74 |
$49,416 |
D/D |
(1,848) |
47,915 |
|
- |
|
| Leite John |
Chief Commercial Officer-CLIA |
• – – |
2025-03-07 |
4 |
AS |
$31.04 |
$234,630 |
D/D |
(7,411) |
100,249 |
|
-14% |
|
| Stapley Marc |
Chief Executive Officer |
• • – |
2025-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
90,601 |
358,636 |
|
- |
|
| Wygant Jonathan |
VP, Chief Accounting Officer |
• – – |
2025-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
13,288 |
49,763 |
|
- |
|
| Leite John |
Chief Commercial Officer-CLIA |
• – – |
2025-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
36,240 |
107,660 |
|
- |
|
| Chambers Rebecca |
Chief Financial Officer |
• – – |
2025-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
30,200 |
143,899 |
|
- |
|
| Mcguire Annie |
SVP, General Counsel |
• – – |
2025-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
30,200 |
100,508 |
|
- |
|
| Febbo Phillip G. |
Chief Scientific & Med Officer |
• – – |
2025-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
24,160 |
106,700 |
|
- |
|
| Febbo Phillip G. |
Chief Scientific & Med Officer |
• – – |
2025-03-04 |
4 |
AS |
$32.86 |
$268,013 |
D/D |
(8,037) |
82,540 |
|
-20% |
|
593 Records found
|
|
Page 1 of 24 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.35 (1.28%) 
